Clinical Trials on McCune-Albright Syndrome

Total 34231 results

Grupo Español de Síndromes Mielodisplásicos

Completed

Spanish Registry of Erythropoietic Stimulating Agents Study (SPRESAS)

Myelodysplastic Syndrome
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Myelodysplastic Syndromes

Italy
Weill Medical College of Cornell University
CTI BioPharma

Completed

Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
University of Florida
Teva Pharmaceutical Industries, Ltd.

Withdrawn

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Shandong University

Unknown

Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent

Myelodysplastic Syndromes

China
Groupe Francophone des Myelodysplasies
Roche Pharma AG

Completed

Erlotinib in Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

France
Apogenix GmbH

Completed

APG101 in Myelodysplastic Syndrome (APG101 in MDS)

Myelodysplastic Syndrome

Germany
The Affiliated Hospital of the Chinese Academy...
The Second Artillery General Hospital

Completed

Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
Ulsan University Hospital
Cooperative Study Group A for Hematology

Unknown

Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome (VIOLET)

Myelodysplastic Syndrome

Korea, Republic of
Virginia Commonwealth University
Celgene Corporation

Completed

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
University of Pittsburgh

Completed

Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Singapore General Hospital
Johnson & Johnson

Terminated

Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients

Myelodysplastic Syndrome

Singapore
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Completed

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia (GFMVOR2007)

Myelodysplastic Syndromes

France
Samsung Medical Center

Completed

Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Kaplan Medical Center
Weizmann Institute of Science

Unknown

The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome

Myelodysplastic Syndrome

Israel
The Vaccine Company

Unknown

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Providence Hospital

Unknown

Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Eisai Inc.

Completed

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome

United States
Johnson & Johnson Taiwan Ltd

Completed

An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Taiwan
Janssen Korea, Ltd., Korea

Completed

A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome
Telik

Completed

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea

No longer available

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Hong Kong, Brazil, Thailand
Texas Oncology Cancer Center
Genzyme, a Sanofi Company

Terminated

Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)

Myelodysplastic Syndromes

United States
Astex Pharmaceuticals, Inc.

Completed

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Myelodysplastic Syndrome

United States
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
European Organisation for Research and Treatment...

Completed

Infliximab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Belgium, Netherlands, Czech Republic, Italy, Germany
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Terminated

Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes

Myelodysplastic Syndromes

Italy
Cooperative Study Group A for Hematology

Unknown

Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS) (CyFluATG)

Myelodysplastic Syndrome

Korea, Republic of
University of Utah
National Institutes of Health (NIH)

Completed

The Role of Erythropoietin in Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome
St. Bartholomew's Hospital

Unknown

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United Kingdom
PETHEMA Foundation

Completed

Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Spain
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States
Hadassah Medical Organization

Withdrawn

The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndrome

Israel
Sohag University
Assiut University; Kyoto University

Recruiting

Mutations and Phenotypes of Unclassifiable Inherited Bone Marrow Failure Syndromes

Inherited BMF Syndrome

Egypt
Jazz Pharmaceuticals
Evidilya S.r.l.

Not yet recruiting

Epidyolex® in Lennox Gastaut and Dravet Syndrome: an Observational Study in ITALY (EpiTALY)

Dravet Syndrome | Lennox Gastaut Syndrome

Italy
Medical University of Silesia

Completed

Comparison the Effects of TECAR With Dry Needling in the Treatment of Myofascial Trigger Points

Myofascial Trigger Point Pain | Myofascial Pain Syndrome of Neck | Myofascial Trigger Point Syndrome

Poland
Eisai Inc.

Terminated

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome (LGS)

Korea, Republic of, United States, Australia, Belgium, Japan, Czechia, India
Gillette Children's Specialty Healthcare
University of Minnesota

Withdrawn

The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy

Dravet Syndrome | Lennox Gastaut Syndrome
Gillette Children's Specialty Healthcare

Terminated

The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy (CBD1)

Dravet Syndrome | Lennox-Gastaut Syndrome

United States
Jazz Pharmaceuticals

Completed

An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes (GWPCARE5)

Epilepsy | Dravet Syndrome | Lennox-Gastaut Syndrome
Shanghai University of Traditional Chinese Medicine
Shanghai Yueyang Integrated Medicine Hospital

Recruiting

Yan Nian Jiu Zhuan Fa Improve Chronic Fatigue Syndromes (YNJZFCFS)

Chronic Fatigue Syndromes

China
Catalyst Pharmaceuticals, Inc.

No longer available

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome (EAP-001)

Lambert-Eaton Myasthenic Syndrome | Congenital Myasthenic Syndrome | Nystagmus, Acquired

United States
Laboratoires Thea

Not yet recruiting

Comparison of the Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

Dry Eye Syndrome
Lindsey Russell, MD
Napo Pharmaceuticals, Inc.

Not yet recruiting

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

Short Bowel Syndrome

United States
AJU Pharm Co., Ltd.
GL Pharm Tech Corporation

Recruiting

Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients

Dry Eye Syndromes

Korea, Republic of
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

Dravet Syndrome

Australia
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome (ENDEAVOR)

Dravet Syndrome

United States

Clinical Trials on McCune-Albright Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations